Matinas BioPharma Holdings (MTNB) Cash & Equivalents (2013 - 2026)

Matinas BioPharma Holdings (MTNB) has 14 years of Cash & Equivalents data on file, last reported at $2.4 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $2.4 million, down 65.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 million (down 65.37% YoY), and the FY2025 annual result was $4.0 million, down 45.1% from the prior year.
• Cash & Equivalents eased to $2.4 million in Q1 2026 per MTNB's latest filing, from $4.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $19.3 million in Q1 2022 and troughed at $1.1 million in Q1 2024.
• A 5-year average of $7.2 million and a median of $6.5 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents jumped 7631.2% in 2022, then slumped 81.34% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $6.8 million in 2022, then declined by 29.91% to $4.8 million in 2023, then soared by 52.16% to $7.3 million in 2024, then slumped by 45.1% to $4.0 million in 2025, then slumped by 40.04% to $2.4 million in 2026.
• Business Quant data shows MTNB's Cash & Equivalents at $2.4 million in Q1 2026, $4.0 million in Q4 2025, and $5.4 million in Q3 2025.